Europe’s joint clinical assessments: what the new HTA era means for evidence teams

A therapy’s journey to patients runs through evidence assessment. Under the EU’s Health Technology Assessment Regulation, joint clinical assessments (JCAs) became applicable from January 2025 — beginning with new oncology medicines and advanced therapies — creating a shared European evaluation of a technology’s comparative clinical evidence that member states use in their national decisions.^[1] For developers and health systems alike, this cooperation reduces duplication and gives evidence planning a clearer target.

What changes for evidence teams

• One dossier, many readers. A joint assessment means anticipating the evidence questions of many member states at once — comparator choices and outcome selection deserve early, careful planning.
• Timelines interlock. JCA submissions run alongside regulatory review, rewarding organisations whose regulatory, HEOR and market-access functions plan as one team.
• Methods literacy matters. Understanding comparative-effectiveness methodology — endpoints, indirect comparisons, uncertainty handling — moves from specialist niche to team-wide need.

The constructive reading

Harmonisation of this kind is a maturation signal: European cooperation building shared scientific infrastructure so that innovation reaches patients through a clearer, more consistent path. Teams that engage early — building JCA thinking into development plans rather than retrofitting it — consistently find the new era navigable and even clarifying.

Three decades of convergence

Europe’s new joint assessments are the destination of a long road. National HTA institutions proliferated from the 1990s onward, each developing its own methods, evidence expectations and processes — scientifically rich, but cumulatively burdensome: a company launching across Europe could face dozens of parallel assessments of the same clinical evidence, each asking subtly different questions on different timelines. Voluntary cooperation came first — the EUnetHTA collaborations piloted joint assessments and common methods over more than a decade — and proved both the value and the limits of goodwill without legal force. The HTA Regulation converts that experience into obligation: joint clinical assessments with defined timelines, beginning with oncology medicines and advanced therapies from January 2025 and expanding in stages toward all centrally authorised medicines.

The design preserves an important balance: the joint work assesses the clinical evidence — relative effectiveness and safety — while pricing, reimbursement and value judgements remain firmly national. One scientific conversation, many national decisions.

What evidence teams should do differently

• Plan for the PICO multiplicity. Joint assessments consolidate the comparator and population questions of many member states; anticipating that breadth during trial design — not after submission — is the core strategic adjustment.
• Use the joint scientific consultation window. Early dialogue on evidence plans is the mechanism for aligning development with what assessors will later ask.
• Resource the timeline realistically. Joint submissions run parallel to regulatory review, compressing dossier work into demanding windows that reward preparation and punish improvisation.
• Keep national fluency. Joint clinical assessment feeds national processes; the craft of national value argumentation, economics and negotiation remains fully alive.

Looking ahead

Expect an adjustment period — first cycles finding their rhythm, methods guidance evolving, all parties learning — followed by something structurally better: less duplicated assessment, earlier clarity on evidence expectations, and, plausibly, faster access for patients in member states that historically waited longest. For professionals, the message is unambiguous: HTA literacy has moved from national specialism to European core competence, and the teams investing in it now will navigate the new era rather than be surprised by it.

Where EUSTM fits

The EUSTM Academy’s Professional Certification in Health Technology Assessment (PCHTA) recognises exactly this competence, and pairs naturally with the Professional Certification in Health Economics & Outcomes Research (PCHEOR) for the full evidence-to-value skill set.

Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.

← All Expert Insights